US biotech major Amgen (Nasdaq: AMGN) reported second quarter 2024 financial results late yesterday, showing total revenues increased 20% to $8.4 billion in comparison to the like quarter of 2023.
Product sales grew 20%, driven by 26% volume growth, partially offset by 3% lower net selling price. Excluding sales from its around $28 billion Horizon Therapeutics acquisition which completed last October, product sales grew 5%, driven by volume growth of 10%.
Amgen reported a net income of $746 million, a $1.38 per diluted share, for the second quarter, a 46% decline compared to $1.38 billion, or $2.570 per diluted share, for the respective quarter in 2023. Amgen’s shares fell 2.1% to $322.00 in after-hours trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze